MedDataX Logo

The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

NCT ID: NCT00205946

Last Updated: 2007-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A cardinal feature of Major Depressive Disorder is anhedonia, which is a lack of pleasure in normally enjoyable activities. In order to understand reward processing in depressed individuals it is also necessary to study reward processing in people who are not depressed. Bupropion, the active drug in the anti-depressant Wellbutrin XL, has been shown to increase brain reward functioning in animals. The goal of the present study is to investigate the effects of Wellbutrin XL administered to psychiatrically healthy individuals as they perform a computer task known to assess reward processing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Reward Processing Wellbutrin Bupropion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)

Bupropion

Group Type ACTIVE_COMPARATOR

Bupropion

Intervention Type DRUG

150 mg of bupropion administered 5 hours before fMRI scanning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupropion

150 mg of bupropion administered 5 hours before fMRI scanning

Intervention Type DRUG

Placebo

Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Wellbutrin XL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse)
* Non-Smoker
* Right-handed (Chapman and Chapman 1987)
* Ability to provide informed consent

Exclusion Criteria

* Predisposition to seizure (e.g. family history of a seizure disorder, history of head trauma) or current use of medications that lower the seizure threshold
* History or current diagnosis of anorexia or bulimia
* Alcohol or substance abuse within the past year
* Current usage of Wellbutrin or Zyban or other drugs that contain bupropion
* Recent discontinuation of alcohol or sedatives (including benzodiazepines)
* Use of (in the last 2 weeks) medications that may have antidepressant properties (ex. some herbal supplements)
* Known allergies to bupropion
* Currently lactating, pregnant or believe you are likely to be pregnant (enrolled subjects who are not using reliable contraception and have engaged in sexual intercourse since their last menstrual period will be given a self-administered pregnancy test.)
* Left-handed/ambidextrous
* Evidence of neurological illness
* Serious suicide or homicide risk
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

Affective Neuroscience Laboratory

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Harvard University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Diego A Pizzagalli, PhD

Role: PRINCIPAL_INVESTIGATOR

Harvard University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Depression Clinical and Research Program, Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Affective Neuroscience Laboratory, Department of Psychology, Harvard University

Cambridge, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2004-P002234-1

Identifier Type: -

Identifier Source: secondary_id

2004-P-002234-1

Identifier Type: -

Identifier Source: org_study_id